![]() | |
Clinical data | |
---|---|
Other names | Cyheptamine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.027.792 |
Chemical and physical data | |
Formula | C16H15NO |
Molar mass | 237.302 g·mol−1 |
3D model (JSmol) | |
| |
|
Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant. [1]
Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways. [2]
Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values. [3]